Xarelto – a relatively new anticoagulant medication – has been linked to severe side effects and adverse reactions such as uncontrollable bleeding and an increased risk of blood clots. Patients who have suffered harmful side effects after taking Xarelto will be looking for a drug injury law firm for legal assistance. Broughton Partners connects personal injury law firms with Xarelto lawsuit leads and other drug injury leads. The leads we deliver to law firms are case-ready and pre-qualified. Law firms looking for more Xarelto lawsuit leads can work with Broughton Partners and start receiving Xarelto lawsuit leads that fit their specific case criteria.
What is Xarelto?
Xarelto (rivaroxaban) was first approved by the FDA in July of 2011. Blood thinners have three main uses:
- Reducing the risk of blood clots and stroke in patients with atrial fibrillation,
- Treating deep vein thrombosis and pulmonary embolisms, and
- Reducing the risk of blood clots in patients undergoing knee or hip replacement surgery.
To treat a clotting disorder (which can lead to strokes or embolisms), a medication like Xarelto may be prescribed which will keep the blood from clotting. As a result of the action of this drug, patients must be very careful to avoid injury, as the blood can no longer clot naturally.
Patients must be very careful to avoid injury, as the blood can no longer clot naturally.
Older blood thinners like Warfarin (Coumadin) have been around for over 50 years. Warfarin has an antidote, and its blood-thinning effects can be reversed with a shot of Vitamin K.
Unlike Warfarin, Xarelto does not have an antidote. If a patient taking Xarelto is injured or needs surgery, there is no shot which will reverse its effects and allow the body to resume clotting normally. Patients who begin hemorrhaging while taking Xarelto may not be able to stop, leading to massive blood loss and possibly death.
Common Side Effects and Complications
Adverse side effects of Xarelto have increased dramatically as the drug becomes more common. Xarelto side effects are being reported at a rate of 2 to 1 over Pradaxa, another new drug thinner on the market. Xarelto has paradoxically been linked to reports of increased blood clots, especially in younger patients who have had hip or knee surgery.
These patients and their doctors have reported clotting complications and serious ailments:
- Pulmonary embolisms
- Deep vein thrombosis
- Excessive blood loss
- Intracranial hemorrhaging
- Gastrointestinal bleeding
Three years ago, a non-profit consumer safety group evaluated the adverse events reported to the Food & Drug Administration and found that Xarelto had been linked to more than 350 adverse events. These events included serious, disabling, and fatal injuries. Nearly half of the events were blood clots.
In 2011, a ROCKET AF clinical trial of Xarelto revealed that the drug was no more effective than Warfarin and the risks were comparable. However, a common side effect of Xarelto was intestinal bleeding.
Xarelto Lawsuits Are Being Filed by Injured Patients
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is dangerous and the manufacturer failed to warn consumers about the risks. Lawsuits claim that doctors have no effective means of combating bleeding in the event of an emergency.
Furthermore, lawsuits filed claim that the manufacturers marketed Xarelto as a superior anticoagulant despite the number of adverse events reported to the FDA. Doctors and medical staff were also allegedly not properly made aware of the risks and how to treat someone using Xarelto in the event of bleeding complications.
Families rely on doctors and medication to keep them healthy. If Xarelto’s manufacturer failed to inform a patient or doctor of the potential side effects, or if a patient has suffered unforeseen adverse reactions after taking Xarelto, they may have grounds to pursue a Xarelto claim and or a Xarelto lawsuit.
Victims of a Xarelto bleeding event may be entitled to compensation for past and future medical bills, lost wages and, their pain and suffering. Broughton Partners works to connect these Xarelto victims and other victims of dangerous drugs with personal injury law firms.
Get Connected With Qualified Xarelto Lawsuit Leads
Victims of Xarelto will begin their search for legal options online and will be looking for drug injury attorneys that can help them. Broughton Partners’ legal case generation services will track Xarelto lawsuit leads as soon as they show interest online and after they call. Our professional intake associates work only to acquire qualified Xarelto lawsuit cases with retained plaintiffs. The in-house call center is staffed 24/7 by highly trained multilingual specialists. Our innovative case-acquisition platform is always being monitored and optimized to track only quality Xarelto leads. We have a hard-working team and an industry-leading case-acquisition platform that allows us to deliver the Xarelto lawsuit leads your law firm wants.
Broughton Partners wants to help your law firm by creating an effective campaign for high-quality Xarelto lawsuit leads and providing you with potential Xarelto cases to increase your revenue. Victims of dangerous drugs such as Xarelto are able to find legal help via our network of websites and targeted online advertising.
Our Xarelto Lawsuit Leads Are Fully Vetted & Signed
Broughton Partners’ goal is to provide law firms with retained Xarelto plaintiffs. However, we don’t stop there. We go further by providing Xarelto lawsuit leads with pre-packaged case documents such as hospital files and drug history. This way your law firm can save time on and start working the case immediately. The Xarelto lawsuit leads that are provided by Broughton Partners are real victims who have legitimate Xarelto cases.
It can be difficult to find Xarelto lawsuit leads, especially leads that are high-quality with retained plaintiffs. Save your law firm’s time and let us do the tedious work for you by examining potential Xarelto lawsuit leads and delivering only the best cases to your law firm.
Broughton Partners Fully Examines All Xarelto Lawsuit Leads
Broughton Partners will only deliver quality Xarelto Lawsuit leads that are pre-qualified and match the case criteria specified by your law firm. Our team of trained specialists will be examining the eligibility of cases and whether or not a patient’s claim qualifies for a Xarelto lawsuit. Our case intake system is built upon unique parameters and algorithms that allow us to dynamically improve case quality and conversion. We do this by running potential plaintiffs through specialized questions and a qualification process based on your law firm’s desired criteria. The Xarelto lawsuit leads that your law firm will receive will be questioned and examined to ensure that they are quality retained plaintiffs.
The Xarelto lawsuit leads that Broughton Partners will deliver must meet the following criteria:
- Potential plaintiffs have suffered from one of the previously mentioned Xarelto side effects as a result of taking Xarelto
- Potential plaintiffs were inadequately warned by Xarelto’s manufacturers about the life-threatening risks of taking Xarelto
History and Xarelto Settlement
In July 2008 the Rivaroxaban, an anticoagulant, was submitted to the FDA for approval in the United States of America. In 2009 the FDA advisory committee found a favorable risk to benefit profile for the drug for use after some knee and hip surgeries to help prevent or reduce the risk of DVT (Deep Vein Thrombosis) or Pulmonary Embolism. In July of 2011, the Federal Drug Administration approved Xarelto, the brand name for the generic drug Rivaroxaban, “to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery”. Later that same year, the FDA approved Xarelto to prevent Stroke in people with certain types of Abnormal Heart Rhythm. Finally, in November of 2012, the FDA approved expanded use of Xarelto to treat and/or reduce the occurrence of blood clots.
At least six state and federal lawsuits were filed in 2014 related to the use of Xarelto. Four of the six were on behalf of a deceased loved one and two were filed by plaintiffs who claim injury due to the use of the drug. The claimants all list excessive or hemorrhagic bleeding after the prescribed use of the drug. The period of ingestion varied from as little as 10 days in one claim and up to eight months in another.
By 2015 many claims had been brought against Xarelto manufacturers Bayer and Johnson and Johnson in relation to excessive bleeding, but in October of 2015, the first suit was brought claiming that the drug failed to prevent stroke. It had been approved for such use by the FDA in 2012. The claimant filed suit on behalf of her father, who died four days after being prescribed and using Xarelto for Atrial Fibrillation. She alleges that the medicine did not prevent stroke as it was prescribed and advertised to do and that her father’s stroke and sudden death were both a direct result of the use of Xarelto and its failure to perform as advertised.
MARCH – CBS News cited a New York Times article about controversial Xarelto research by the Duke Clinical Research Institute and findings that may have been withheld. The controversy surrounds results shared by Duke researchers in The New England Journal of Medicine and the possibility that the results may have been skewed by faulty testing equipment. The original testing was used to measure Xarelto’s effectiveness against Warfarin, another more common clotting drug.
AUGUST – The FDA failed to approve an antidote to the anticoagulants Xarelto and Eliquis. The drugs themselves were approved as anticoagulants in 2012 by the Food and Drug Administration, specifically for treating atrial fibrillation and preventing resulting blood clots from that condition. (Xarelto had been approved earlier, in 2009 for use after hip replacement and knee replacement surgeries as a preventative measure against DVT (Deep Vein Thrombosis) and/or Pulmonary Embolism, and the drug’s use approval was expanded to include treatment of or prevention from blood clots due to Atrial Fibrillation) The antidote was created for use in cases where excessive bleeding or hemorrhaging occurred in patients who used Xarelto and other drugs of its kind. The medication, called AndexXa, was developed to “act as a decoy” for the medication in Xarelto, which would allow a patient’s body to develop blood clots, thereby slowing or stopping excessive bleeding. The FDA has not outright denied the approval of AndexXa but has delayed its approval pending further information regarding usage, manufacturing practices, and clinical studies.
OCTOBER – Over 9000 cases had been filed against the makers of Xarelto, including over 7000 in Louisiana and around 1000 in both Philadelphia and Delaware. The claimants allege that use of the drug caused severe bleeding that resulted in critical injury and, in some cases, death and that consumers had not been properly warned of these possible risks related to the use of the product.
FEBRUARY – Because complaints and questions about the law are common in many of the cases filed across the nation, four “bellwether” cases have been scheduled to begin in February of 2017. A bellwether case is a sort of a “test case” that is used when there are many similarities in a multidistrict litigation. The outcome of a bellwether trial is not binding on other plaintiffs’ cases but does offer an idea of the outcome of other cases which help in negotiations and possible settlements. The cases were chosen specifically for a federal judge’s detailed orders of process from a pool of cases representing the commonality of arguments and facts. Because of the overwhelming number of cases being filed against the manufacturers and distributors of Xarelto, this process and these cases are chosen to expedite the process so that the volume of cases does not overload the judicial system.
MARCH – Bayer and Johnson & Johnson agreed to a settlement payout of $775 million to settle 25,000 lawsuits against their blood thinner, Xarelto. Patients were not adequately warned about the harmful side effects of Xarelto and have suffered life-threatening complications. The two pharmaceutical companies will split the cost and pay $387.5 million each, which is pocket change for these large multi-billion dollar companies. Neither company is admitting liability for the claims of Xarelto complications, which is common in drug injury lawsuits. The amount of money each plaintiff will receive is dependent on various factors such as the severity of injuries and when they filed their lawsuit.
The number of cases filed against the manufacturers of Xarelto continues to grow and victims will be seeking dangerous drug lawyers for legal representation.
Would you like to represent more claimants injured by Xarelto?
The ability to bring in new Xarelto cases in a cost-effective way without sacrificing the needs of your current clients and the daily demands of your practice is a challenge at best. Broughton Partners is here to give you a competitive advantage by connecting you with more qualified Xarelto lawsuit leads that are ready and need your representation today.
Start reaching your goals and take your practice to the next level with new Xarelto lawsuit leads? Call Broughton Partners today at (855) 463-1735, or contact us for your free consultation. Together we can ensure there is No Claimant without a Claim.
- Kevin McGill. “$775 million settlement reached in lawsuits over Xarelto blood thinner”, USA Today, https://www.usatoday.com/story/money/2019/03/26/xarelto-lawsuits-775-m-settlement-reached-cases-over-blood-thinner/3274432002/. Accessed May 21, 2019.
- Joe Nocera. “Xarelto Settlement Is a Missed Chance to Stanch the Bleeding”, Bloomber, https://www.bloomberg.com/opinion/articles/2019-04-02/xarelto-settlement-is-missed-chance-for-pharma-to-deter-lawsuits. Accessed May 21, 2019.
- WebMD. “Xarelto”, WebMd, https://www.webmd.com/drugs/2/drug-156265-1153/xarelto-oral/rivaroxaban-oral/details. Accessed May 21, 2019.
- MedlinePlus. “Rivaroxaban”, U.S. National Library of Medicine, https://medlineplus.gov/druginfo/meds/a611049.html. Accessed May 21, 2019.
- Mayo Clinic. “Rivaroxaban (Oral Route)”, Mayo Clinic, https://www.mayoclinic.org/drugs-supplements/rivaroxaban-oral-route/side-effects/drg-20075013. Accessed May 21, 2019.
- Drugs.com. “Xarelto Approval History”, Drugs.com, https://www.drugs.com/history/xarelto.html. Accessed May 21, 2019.